{"id":"W4200255107","doi":"10.1200/jco.21.00931","title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Cilag; Genentech; MorphoSys; Yuhan; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Karyopharm Therapeutics; MEI Pharma; Sunesis; Juno Therapeutics; Celltrion; Adaptive Biotechnologies; Loxo Oncology; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Pfizer; Incyte; F. Hoffmann-La Roche; University of Pennsylvania; Janssen Biotech; Teva Pharmaceutical Industries; Unum Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Gilead Sciences; GlaxoSmithKline; Amgen; LAM Therapeutics; Alimera Sciences; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Safety profile; Phases of clinical research; Clinical trial; Cancer; Stage (stratigraphy); Maximum tolerated dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002569112,0.0001956608,0.001483204,0.0002132098,0.00007688715,0.00002061867,0.0001721341,0.0002566437,0.0007482075],"category_scores_gemma":[0.003456363,0.0001186491,0.0002594109,0.0003512589,0.0001858005,0.0001599901,0.00009503898,0.001104485,0.00002759227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000406951,"about_ca_system_score_gemma":0.002945615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003813067,"about_ca_topic_score_gemma":0.0002181148,"domain_scores_codex":[0.9942738,0.001615536,0.002459486,0.0003199968,0.0009707059,0.0003604972],"domain_scores_gemma":[0.9934853,0.003704001,0.001097937,0.0002752259,0.0009840176,0.000453481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2103226,0.06287921,0.6524192,0.00006675053,0.0003648564,0.008548298,0.0003266933,0.00002126726,0.001727637,0.000006095355,0.002051857,0.06126551],"study_design_scores_gemma":[0.06817798,0.1015584,0.7715471,0.0001529429,0.0001975109,0.0001807504,0.0004785151,0.0001292393,0.0001812987,0.00002093256,0.05723088,0.0001443579],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947761,0.0002355879,0.00001535193,0.002176553,0.0004929728,0.0004395582,0.00001580289,0.000007983818,0.001840082],"genre_scores_gemma":[0.9920847,0.0001761998,0.001636939,0.0009960709,0.0003813158,0.000005352885,0.00002167583,0.00002419706,0.004673516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1421447,"threshold_uncertainty_score":0.8192347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1932406315214324,"score_gpt":0.4643134210697562,"score_spread":0.2710727895483238,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}